StingeniL, HanselK, AntonelliE, et al.Atopic dermatitis in adolescents: effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy. Dermatol Ther. 2021; 34:e15035. . Epub ahead of print.
2.
RossiM, RovatiC, ArisiM, et al.Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: a single-center real-life experience. Dermatol Ther, 2020; 33(4):e13765.
3.
ChiricozziA, TalamontiM, De SimoneC, et alDA-COVID-19 study group. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry. Allergy, 2021; 76(6):1813–1824.
4.
GoriN, ChiricozziA, MalvasoD, et al.Successful combination of systemic agents for the treatment of atopic dermatitis resistant to dupilumab therapy. Dermatology, 2021; 237(4):535–541.
5.
DeleuranM, ThaçiD, BeckLA, et al.Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol, 2020; 82(2):377–388.
